CA3232022A1 - Methods of modulating drug plasma levels using erythrohydroxybupropion - Google Patents

Methods of modulating drug plasma levels using erythrohydroxybupropion Download PDF

Info

Publication number
CA3232022A1
CA3232022A1 CA3232022A CA3232022A CA3232022A1 CA 3232022 A1 CA3232022 A1 CA 3232022A1 CA 3232022 A CA3232022 A CA 3232022A CA 3232022 A CA3232022 A CA 3232022A CA 3232022 A1 CA3232022 A1 CA 3232022A1
Authority
CA
Canada
Prior art keywords
dextromethorphan
bupropion
day
human
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3232022A
Other languages
English (en)
French (fr)
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antecip Bioventures II LLC
Original Assignee
Antecip Bioventures II LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56014366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3232022(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/550,618 external-priority patent/US9198905B2/en
Priority claimed from US14/602,177 external-priority patent/US9402843B2/en
Application filed by Antecip Bioventures II LLC filed Critical Antecip Bioventures II LLC
Publication of CA3232022A1 publication Critical patent/CA3232022A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3232022A 2014-11-21 2015-05-01 Methods of modulating drug plasma levels using erythrohydroxybupropion Pending CA3232022A1 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US14/550,618 2014-11-21
US14/550,618 US9198905B2 (en) 2013-11-05 2014-11-21 Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US14/554,988 US9205083B2 (en) 2013-11-05 2014-11-26 Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
US14/554,947 US20150126542A1 (en) 2013-11-05 2014-11-26 Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects
US14/554,988 2014-11-26
US14/555,085 US9238032B2 (en) 2013-11-05 2014-11-26 Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US14/554,947 2014-11-26
US14/555,085 2014-11-26
US14/602,177 2015-01-21
US14/602,177 US9402843B2 (en) 2013-11-05 2015-01-21 Compositions and methods of using threohydroxybupropion for therapeutic purposes
US14/604,397 2015-01-23
US14/604,397 US9168234B2 (en) 2013-11-05 2015-01-23 Bupropion as a modulator of drug activity
US14/617,624 2015-02-09
US14/617,624 US9486450B2 (en) 2013-11-05 2015-02-09 Hydroxybupropion and related compounds as modulators of drug plasma levels
US14/628,062 2015-02-20
US14/628,062 US9402844B2 (en) 2013-11-05 2015-02-20 Methods of modulating drug plasma levels using erythrohydroxybupropion
CA3082645A CA3082645C (en) 2014-11-21 2015-05-01 Combinations of bupropion and dextromethorphan and uses thereof for the treatment of pain or neurological disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3082645A Division CA3082645C (en) 2014-11-21 2015-05-01 Combinations of bupropion and dextromethorphan and uses thereof for the treatment of pain or neurological disorders

Publications (1)

Publication Number Publication Date
CA3232022A1 true CA3232022A1 (en) 2016-05-26

Family

ID=56014366

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3232022A Pending CA3232022A1 (en) 2014-11-21 2015-05-01 Methods of modulating drug plasma levels using erythrohydroxybupropion
CA2968371A Active CA2968371C (en) 2014-11-21 2015-05-01 Methods of modulating drug plasma levels using erythrohydroxybupropion
CA3082645A Active CA3082645C (en) 2014-11-21 2015-05-01 Combinations of bupropion and dextromethorphan and uses thereof for the treatment of pain or neurological disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2968371A Active CA2968371C (en) 2014-11-21 2015-05-01 Methods of modulating drug plasma levels using erythrohydroxybupropion
CA3082645A Active CA3082645C (en) 2014-11-21 2015-05-01 Combinations of bupropion and dextromethorphan and uses thereof for the treatment of pain or neurological disorders

Country Status (22)

Country Link
EP (2) EP3220909B2 (https=)
JP (5) JP6602863B2 (https=)
KR (7) KR101931896B1 (https=)
CN (2) CN111297860A (https=)
AU (4) AU2015350559C1 (https=)
CA (3) CA3232022A1 (https=)
CY (1) CY1123571T1 (https=)
DK (1) DK3220909T3 (https=)
ES (1) ES2835304T3 (https=)
HR (1) HRP20201855T1 (https=)
HU (1) HUE052609T2 (https=)
IL (4) IL297349B2 (https=)
LT (1) LT3220909T (https=)
MX (3) MX2017006653A (https=)
MY (1) MY189466A (https=)
PL (1) PL3220909T3 (https=)
PT (1) PT3220909T (https=)
RS (1) RS61113B1 (https=)
SG (2) SG11201704066VA (https=)
SI (1) SI3220909T1 (https=)
SM (1) SMT202000639T1 (https=)
WO (1) WO2016081027A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
CA3232022A1 (en) * 2014-11-21 2016-05-26 Antecip Bioventures Ii Llc Methods of modulating drug plasma levels using erythrohydroxybupropion
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
SMT202600055T1 (it) * 2019-01-07 2026-03-09 Antecip Bioventures Ii Llc Combinazione di destrometorfano e bupropione per trattare la depressione in pazienti asiatici
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
EP4183391A4 (en) * 2020-07-20 2024-04-17 Shenzhen Salubris Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION AND ITS USE
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
EP1986639A4 (en) * 2006-02-03 2010-04-28 Avanir Pharmaceuticals PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
WO2009006194A1 (en) 2007-06-28 2009-01-08 Avanir Pharmaceuticals Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
WO2012118562A1 (en) 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20130274282A1 (en) * 2012-04-16 2013-10-17 Herriot Tabuteau Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MY179696A (en) 2013-11-05 2020-11-11 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan
US9402843B2 (en) 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
US9198905B2 (en) 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
CA3232022A1 (en) 2014-11-21 2016-05-26 Antecip Bioventures Ii Llc Methods of modulating drug plasma levels using erythrohydroxybupropion

Also Published As

Publication number Publication date
MX2017006653A (es) 2017-10-31
RS61113B1 (sr) 2020-12-31
JP2020023527A (ja) 2020-02-13
JP2017535563A (ja) 2017-11-30
CN111297860A (zh) 2020-06-19
JP6842129B2 (ja) 2021-03-17
EP3220909A1 (en) 2017-09-27
KR102822654B1 (ko) 2025-06-18
AU2019201548B2 (en) 2020-11-26
HRP20201855T1 (hr) 2021-04-02
IL280905A (en) 2021-04-29
AU2015350559C1 (en) 2019-07-11
KR102253986B1 (ko) 2021-05-21
IL314982A (en) 2024-10-01
EP3220909B1 (en) 2020-09-02
MX2021001442A (es) 2023-01-05
CA3082645A1 (en) 2016-05-26
SMT202000639T1 (it) 2021-01-05
CA2968371A1 (en) 2016-05-26
WO2016081027A1 (en) 2016-05-26
AU2021200981B2 (en) 2024-06-20
ES2835304T3 (es) 2021-06-22
IL252417A0 (en) 2017-07-31
JP6602863B2 (ja) 2019-11-06
KR102640586B1 (ko) 2024-02-23
JP2023041862A (ja) 2023-03-24
JP2025105965A (ja) 2025-07-10
MX2023000320A (es) 2023-02-09
CY1123571T1 (el) 2022-03-24
PT3220909T (pt) 2020-12-07
AU2021200981A1 (en) 2021-03-11
MY189466A (en) 2022-02-15
EP3220909A4 (en) 2018-07-11
CN107205998A (zh) 2017-09-26
AU2019201548A1 (en) 2019-03-28
AU2019201548C1 (en) 2021-09-16
KR20230056795A (ko) 2023-04-27
SG11201704066VA (en) 2017-06-29
EP3220909B2 (en) 2026-02-18
KR20170088926A (ko) 2017-08-02
KR20180136003A (ko) 2018-12-21
IL252417B (en) 2021-03-25
KR20220038820A (ko) 2022-03-29
IL297349B2 (en) 2025-01-01
AU2015350559A1 (en) 2017-06-08
IL297349A (en) 2022-12-01
HUE052609T2 (hu) 2021-05-28
IL280905B (en) 2022-11-01
DK3220909T3 (da) 2020-11-23
LT3220909T (lt) 2021-01-25
JP7226839B2 (ja) 2023-02-21
KR102524253B1 (ko) 2023-04-20
HK1243323A1 (zh) 2018-07-13
CA3082645C (en) 2024-04-16
SI3220909T1 (sl) 2021-01-29
IL280905B2 (en) 2023-03-01
KR20250092295A (ko) 2025-06-23
KR20240027872A (ko) 2024-03-04
AU2024219871A1 (en) 2024-10-10
CA2968371C (en) 2020-08-18
KR20210059788A (ko) 2021-05-25
JP2021066744A (ja) 2021-04-30
KR102376868B1 (ko) 2022-03-18
KR101931896B1 (ko) 2018-12-21
SG10201911873XA (en) 2020-02-27
IL297349B1 (en) 2024-09-01
EP3763372A1 (en) 2021-01-13
AU2015350559B2 (en) 2018-12-06
PL3220909T3 (pl) 2021-04-06

Similar Documents

Publication Publication Date Title
AU2021200981B2 (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
US9278095B2 (en) Bupropion as a modulator of drug activity
US9408815B2 (en) Bupropion as a modulator of drug activity
US9421176B1 (en) Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
CA2929415C (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40035510A (en) Treatments comprising a combination of dextromethorphan and bupropion
HK1243323B (en) Bupropion for modulating drug plasma levels of dextrometorphan

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240314

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250306

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250704

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250708

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250710

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250710

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250717

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250717

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251229

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251229

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260415